Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational research

BACKGROUND: Despite the introduction of novel effective treatment regimens like gemcitabine plus nab-paclitaxel and FOLFIRINOX, pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive epithelial tumors. Among the genetic alterations frequently found in PDAC, mutations in the KRAS...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMC Cancer
Hauptverfasser: Baechmann, Sibylle, Ormanns, Steffen, Haas, Michael, Kruger, Stephan, Remold, Anna, Modest, Dominik Paul, Kirchner, Thomas, Jung, Andreas, Werner, Jens, Heinemann, Volker, Boeck, Stefan
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2017
Schlagworte:
Case Report
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5445280/
https://ncbi.nlm.nih.gov/pubmed/28549417
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-017-3376-4
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge